The Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy

European Urology

Volumn 51, Issue 4, 2007, Pages 940-948

  Yossepowitch, Ofer ^a   Bianco Jr , Fernando J ^a   Eggener, Scott E ^a   Eastham, James A ^a   Scher, Howard I ^a   Scardino, Peter T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hormonal therapy; Metastasis; Natural history; Prostate cancer; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; VISCERAL METASTASIS;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 33847091156     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.10.045     Document Type: Article

References (20)

1. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
2. Loblaw D.A., Mendelson D.S., Talcott J.A., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22 (2004) 2927-2941
3. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
4. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
5. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141-1147
6. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
7. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
8. Chodak G.W., Vogelzang N.J., Caplan R.J., Soloway M., and Smith J.A. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 265 (1991) 618-621
9. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
10. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998) 1036-1042
11. Thompson I.M., Tangen C., Basler J., and Crawford E.D. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168 (2002) 1008-1012
12. Zagars G.K., Pollack A., and von Eschenbach A.C. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58 (2001) 233-239
13. Cadeddu J.A., Partin A.W., Epstein J.I., Walsh P.C., and Stage D1. (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 50 (1997) 251-255
14. Soloway M.S., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167 (2002) 112-116
15. Tangen C.M., Faulkner J.R., Crawford E.D., et al. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2 (2003) 41-45
16. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163-2172
17. Stewart A.J., Scher H.I., Chen M.H., et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23 (2005) 6556-6560
18. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
19. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
20. Sabbatini P., Larson S.M., Kremer A., et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17 (1999) 948-957